(Q43279625)

18 November 2017

title

Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder (English)

1 reference

18 November 2017

R Bruce Lydiard

1

1 reference

18 November 2017

Karl Rickels

series ordinal

2

1 reference

18 November 2017

Barry Herman

series ordinal

3

1 reference

18 November 2017

Douglas E Feltner

series ordinal

4

1 reference

18 November 2017

publication date

9 September 2009

1 reference

The International Journal of Neuropsychopharmacology

18 November 2017

published in

1 reference

18 November 2017

volume

13

1 reference

18 November 2017

issue

2

1 reference

18 November 2017

page(s)

229-241

1 reference

Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Dosing strategies for antidepressant clinical trials: a commentary

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Long-term Treatment of Anxiety and Risk of Withdrawal

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Fear and anxiety: divergent effects on human pain thresholds.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF-REPORT RATINGS OF HOSPITALIZED DEPRESSIVES

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Chronicity, relapse, and illness--course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

10.1017/S1461145709990460

Identifiers

DOI

1 reference

18 November 2017

1 reference